Loading...

BioScrip

DB:MM6
Snowflake Description

Mediocre balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MM6
DB
$481M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

BioScrip, Inc. provides infusion solutions in the United States. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • BioScrip has significant price volatility in the past 3 months.
MM6 Share Price and Events
7 Day Returns
-1.2%
DB:MM6
-0.6%
DE Healthcare
0%
DE Market
1 Year Returns
36.3%
DB:MM6
-33%
DE Healthcare
-19.4%
DE Market
MM6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioScrip (MM6) -1.2% -3.5% 26.7% 36.3% 98.4% -47.1%
DE Healthcare -0.6% 3.3% -21.7% -33% -22.8% 10.3%
DE Market 0% 1.2% -5% -19.4% 6.4% 2%
1 Year Return vs Industry and Market
  • MM6 outperformed the Healthcare industry which returned -33% over the past year.
  • MM6 outperformed the Market in Germany which returned -19.4% over the past year.
Price Volatility
MM6
Industry
5yr Volatility vs Market

MM6 Value

 Is BioScrip undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioScrip to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioScrip.

DB:MM6 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:MM6
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 9.8%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.49
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.493 (1 + (1- 21%) (103.62%))
0.897
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.897 * 9.77%)
9%

Discounted Cash Flow Calculation for DB:MM6 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioScrip is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:MM6 DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) 16.37 16.25 16.12 16.00 15.88
Source Analyst x2 Est @ -0.76% Est @ -0.76% Est @ -0.76% Est @ -0.76%
Present Value
Discounted (@ 9%)
15.02 13.67 12.45 11.34 10.32
Present value of next 5 years cash flows $62.80
DB:MM6 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $15.88 × (1 + 0.23%) ÷ (9% – 0.23%)
$181.49
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $181.49 ÷ (1 + 9%)5
$117.97
DB:MM6 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $62.80 + $117.97
$180.77
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $180.77 / 128.04
$1.23
DB:MM6 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:MM6 represents 0.86968x of NasdaqGS:BIOS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86968x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 1.41 x 0.86968
€1.23
Value per share (EUR) From above. €1.23
Current discount Discount to share price of €3.27
= -1 x (€3.27 - €1.23) / €1.23
-166.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of BioScrip is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioScrip's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioScrip's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MM6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.38
NasdaqGS:BIOS Share Price ** NasdaqGS (2019-01-18) in USD $3.76
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 19.2x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 17.35x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioScrip.

DB:MM6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BIOS Share Price ÷ EPS (both in USD)

= 3.76 ÷ -0.38

-9.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioScrip is loss making, we can't compare its value to the DE Healthcare industry average.
  • BioScrip is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BioScrip's expected growth come at a high price?
Raw Data
DB:MM6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
57.3%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.49x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.31x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioScrip, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioScrip's assets?
Raw Data
DB:MM6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $-0.99
NasdaqGS:BIOS Share Price * NasdaqGS (2019-01-18) in USD $3.76
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.4x
Germany Market PB Ratio Median Figure of 566 Publicly-Listed Companies 1.75x
DB:MM6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BIOS Share Price ÷ Book Value per Share (both in USD)

= 3.76 ÷ -0.99

-3.79x

* Primary Listing of BioScrip.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioScrip has negative assets, we can't compare the value of its assets to the DE Healthcare industry average.
X
Value checks
We assess BioScrip's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. BioScrip has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MM6 Future Performance

 How is BioScrip expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
57.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioScrip expected to grow at an attractive rate?
  • Unable to compare BioScrip's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare BioScrip's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • BioScrip's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MM6 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MM6 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 57.3%
DB:MM6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 6.4%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 4.4%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MM6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MM6 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 811 -10 6
2019-12-31 762 25 -27 7
2018-12-31 714 16 -49 7
DB:MM6 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 708 -12 -49
2018-06-30 726 -16 -53
2018-03-31 768 5 -67
2017-12-31 817 -1 -73
2017-09-30 875 -13 -78
2017-06-30 901 -26 -76
2017-03-31 915 -43 -55
2016-12-31 936 -43 -45
2016-09-30 939 -37 -55
2016-06-30 962 -40 -68
2016-03-31 976 -48 -306
2015-12-31 982 -64 -315

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioScrip is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • BioScrip's revenue is expected to grow by 6.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MM6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from BioScrip Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MM6 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.07 0.10 -0.15 5.00
2019-12-31 -0.21 -0.19 -0.25 5.00
2018-12-31 -0.38 -0.37 -0.39 5.00
DB:MM6 Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.38
2018-06-30 -0.42
2018-03-31 -0.53
2017-12-31 -0.59
2017-09-30 -0.65
2017-06-30 -0.64
2017-03-31 -0.52
2016-12-31 -0.48
2016-09-30 -0.68
2016-06-30 -0.97
2016-03-31 -4.46
2015-12-31 -4.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioScrip will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioScrip's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioScrip has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MM6 Past Performance

  How has BioScrip performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioScrip's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioScrip does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare BioScrip's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioScrip's 1-year growth to the DE Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
BioScrip's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioScrip Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MM6 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 707.92 -48.80 49.43
2018-06-30 725.65 -53.47 52.84
2018-03-31 767.96 -67.22 57.68
2017-12-31 817.19 -73.38 63.32
2017-09-30 874.73 -78.44 63.37
2017-06-30 900.58 -76.22 65.15
2017-03-31 914.94 -55.12 63.07
2016-12-31 935.59 -45.26 65.41
2016-09-30 939.21 -55.01 68.86
2016-06-30 961.89 -67.91 68.83
2016-03-31 976.33 -306.27 82.16
2015-12-31 982.22 -314.63 84.92
2015-09-30 978.22 -357.45 -14.13
2015-06-30 962.46 -370.34 50.40
2015-03-31 927.72 -143.58 83.13
2014-12-31 922.65 -149.92 128.86
2014-09-30 908.39 -102.16 277.02
2014-06-30 867.57 -86.71 250.93
2014-03-31 827.62 -73.81 244.85
2013-12-31 696.47 -71.64 67.41
2013-09-30 724.71 -42.83 212.38
2013-06-30 704.45 -19.68 206.52
2013-03-31 688.13 -14.76 200.67
2012-12-31 593.45 -12.28 176.08
2012-09-30 640.16 -4.36 192.13
2012-06-30 603.63 -4.09 187.32
2012-03-31 579.30 -1.43 182.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioScrip has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • BioScrip used its assets less efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • It is difficult to establish if BioScrip improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioScrip's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioScrip has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MM6 Health

 How is BioScrip's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioScrip's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioScrip is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioScrip's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of BioScrip's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioScrip has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioScrip Company Filings, last reported 3 months ago.

DB:MM6 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -36.34 498.85 18.94
2018-06-30 -29.48 493.27 20.82
2018-03-31 -15.48 481.44 30.35
2017-12-31 -2.67 480.59 39.46
2017-09-30 1.44 478.58 33.01
2017-06-30 13.38 477.41 40.53
2017-03-31 26.53 472.50 15.97
2016-12-31 38.38 451.93 9.57
2016-09-30 45.35 436.24 2.84
2016-06-30 49.24 399.46 51.43
2016-03-31 -26.44 423.93 8.05
2015-12-31 -17.96 418.12 15.58
2015-09-30 -0.36 448.92 29.44
2015-06-30 14.69 418.86 1.17
2015-03-31 258.23 418.83 23.25
2014-12-31 216.81 423.80 0.74
2014-09-30 278.53 423.28
2014-06-30 315.02 418.74 1.55
2014-03-31 332.66 418.67 9.25
2013-12-31 354.58 435.58 1.00
2013-09-30 370.34 415.61
2013-06-30 400.90 225.50 81.64
2013-03-31 287.47 253.36
2012-12-31 293.41 226.38 62.10
2012-09-30 283.52 226.45 67.18
2012-06-30 294.90 257.45 138.42
2012-03-31 214.68 291.37
  • BioScrip has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if BioScrip's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioScrip has sufficient cash runway for more than 3 years based on current free cash flow.
  • BioScrip has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -78.9% each year.
X
Financial health checks
We assess BioScrip's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioScrip has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MM6 Dividends

 What is BioScrip's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioScrip dividends.
If you bought €2,000 of BioScrip shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioScrip's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioScrip's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MM6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MM6 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioScrip has not reported any payouts.
  • Unable to verify if BioScrip's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioScrip's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioScrip has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioScrip's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioScrip afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioScrip has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MM6 Management

 What is the CEO of BioScrip's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dan Greenleaf
COMPENSATION $2,394,549
AGE 53
TENURE AS CEO 2.3 years
CEO Bio

Mr. Daniel E. Greenleaf, also known as Dan, has been the Chief Executive Officer and President at BioScrip, Inc. since September 9, 2016. Mr. Greenleaf has over 21 years of relevant experience in senior leadership positions in the healthcare industry. Mr. Greenleaf served as the Chief Executive Officer at Home Solutions Inc. since December 13, 2013 and Chairman of the Board since 2013. Mr. Greenleaf served as President at Home Solutions Inc. since December 13, 2013. Mr. Greenleaf served as the Chief Executive Officer of Coram, Inc. (also known as Coram LLC), a home infusion business unit of Apria Healthcare Group Inc. from March 14, 2012 to November 29, 2012. Mr. Greenleaf served as the Chief Operating Officer of Coram Specialty Infusion Services, Inc. since March 2012 and also served as its Chief Executive Officer since April 2012 until 2013. Mr. Greenleaf served as the Chief Operating Officer/Chief Operating Officer of Home Respiratory/Home Medical Equipment Segment at Apria Healthcare Group Inc. from November 30, 2010 to March 14, 2012. Mr. Greenleaf served as the President of Coram Specialty Infusion Services from April 2008 to March 2012. He served as President and Chief Executive Officer of VioQuest Pharmaceuticals Inc. of Chiral Quest Inc. from February 7, 2005 to November 9, 2007. He served as the President of Coram Inc. from April 2008 to March 14, 2012 and as its Chief Operating Officer from 2010 to March 14, 2012. Mr. Greenleaf joined VioQuest Pharmaceuticals Inc. from Celltech Biopharmaceuticals, where he served as President of their U.S. operations since 2004. Prior to Celltech, he served as Senior Vice President of Operations of Nabi Biopharmaceuticals Inc. since November 2002. From 1992 to 2002, Mr. Greenleaf was employed by Schering-Plough Corporation, including as its Vice President of Marketing and Sales from 2000 to 2002. While at Schering-Plough Corporation, he held various positions of increasing responsibility in sales, marketing and strategic venture including the creation of a wholly owned, global subsidiary. From 1988 to 1992, Mr. Greenleaf served in the United States Air Force as Captain and Navigator and coordinated missions for worldwide tactical airlift operations, including Operation Desert Storm. He has been a Director of BioScrip, Inc. since September 9, 2016. He served as a Director of BioNJ Inc. (formerly, Biotechnology Council of New Jersey). He served as a Director of Vioquest Pharmaceuticals Inc. from February 7, 2005 to November 9, 2007. He serves on the University of Miami's Health Sector Management and Policy Board. He has also been a member of the international group, Young President's Organization (YPO), since 2004. He was a board member for the National Home Infusion Association (NHIA). Mr. Greenleaf received his MBA in Health Administration from the University of Miami in 1997 and graduated from Denison University in 1987 with a Bachelor of Arts (BA) degree in Economics.

CEO Compensation
  • Dan's compensation has increased whilst company is loss making.
  • Dan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioScrip management team in years:

1.5
Average Tenure
53
Average Age
  • The average tenure for the BioScrip management team is less than 2 years, this suggests a new team.
Management Team

Dan Greenleaf

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
53
TENURE
2.3 yrs

Steve Deitsch

TITLE
Senior VP
COMPENSATION
$1M
AGE
45
TENURE
1.8 yrs

Harriet Booker

TITLE
Senior VP & COO
COMPENSATION
$760K
AGE
51
TENURE
1.2 yrs

Jody Kepler

TITLE
Senior VP
COMPENSATION
$350K
AGE
48
TENURE
2.1 yrs

John McMahon

TITLE
Chief Accounting Officer
AGE
53
TENURE
0.3 yrs

Vito Ponzio

TITLE
Chief Administrative Officer & Senior VP
COMPENSATION
$828K
AGE
63

Kathryn Stalmack

TITLE
Senior VP
TENURE
3.4 yrs

Leslie McIntosh

TITLE
SVP & Chief Human Resources Officer
TENURE
0.5 yrs

Bob Roose

TITLE
Chief Procurement Officer & Senior VP
COMPENSATION
$552K
AGE
60

Rich Denness

TITLE
Senior VP & Chief Commercial Officer
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the BioScrip board of directors in years:

2.8
Average Tenure
56
Average Age
  • The average tenure for the BioScrip board of directors is less than 3 years, this suggests a new board.
Board of Directors

R. Pate

TITLE
Non-Executive Chairman
COMPENSATION
$266K
AGE
63
TENURE
2.6 yrs

Dan Greenleaf

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
53
TENURE
2.3 yrs

David Golding

TITLE
Director
COMPENSATION
$161K
AGE
56
TENURE
3.7 yrs

Michael Goldstein

TITLE
Director
COMPENSATION
$161K
AGE
76
TENURE
3.7 yrs

Michael Bronfein

TITLE
Director
COMPENSATION
$160K
AGE
62
TENURE
2.8 yrs

Chris Shackelton

TITLE
Director
COMPENSATION
$145K
AGE
38
TENURE
3.8 yrs

Steve Neumann

TITLE
Director
COMPENSATION
$132K
AGE
50
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Nov 18 Sell Teton Advisors, Inc Company 19. Oct 18 26. Nov 18 -22,448 €3.28 €-66,637
27. Nov 18 Sell GAMCO Investors, Inc. Company 27. Sep 18 26. Nov 18 -776,691 €3.19 €-9,725
27. Nov 18 Buy GAMCO Investors, Inc. Company 12. Oct 18 26. Oct 18 63,573 €2.41 €59,343
13. Aug 18 Sell GAMCO Investors, Inc. Company 13. Jun 18 10. Aug 18 -1,006,894 €2.82 €-2,818,357
13. Aug 18 Buy GAMCO Investors, Inc. Company 13. Jun 18 09. Jul 18 150,000 €2.58 €386,870
X
Management checks
We assess BioScrip's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioScrip has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MM6 News

External News
Loading...
Simply Wall St News

MM6 Company Info

Map
Description

BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient’s homes, outpatient clinics, nursing facilities, physician’s offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Details
Name: BioScrip, Inc.
MM6
Exchange: DB
Founded: 1993
$423,903,112
128,041,101
Website: http://www.bioscrip.com
Address: BioScrip, Inc.
1600 Broadway,
Suite 700,
Denver,
Colorado, 80202,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BIOS Common Stock Nasdaq Global Select US USD 15. Aug 1996
DB MM6 Common Stock Deutsche Boerse AG DE EUR 15. Aug 1996
XTRA MM6 Common Stock XETRA Trading Platform DE EUR 15. Aug 1996
Number of employees
Current staff
Staff numbers
1,752
BioScrip employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/18 21:20
End of day share price update: 2019/01/18 00:00
Last estimates confirmation: 2018/12/12
Last earnings filing: 2018/11/06
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.